Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


DNA methylation changes in a human cell model of breast cancer progression.

Fernandez SV, Snider KE, Wu YZ, Russo IH, Plass C, Russo J.

Mutat Res. 2010 Jun 1;688(1-2):28-35. doi: 10.1016/j.mrfmmm.2010.02.007.


Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation.

Wu Y, Alvarez M, Slamon DJ, Koeffler P, Vadgama JV.

BMC Cancer. 2010 Feb 4;10:32. doi: 10.1186/1471-2407-10-32.


XAF1 is frequently methylated in human esophageal cancer.

Chen XY, He QY, Guo MZ.

World J Gastroenterol. 2012 Jun 14;18(22):2844-9. doi: 10.3748/wjg.v18.i22.2844.


All trans-retinoic acid (ATRA) induces re-differentiation of early transformed breast epithelial cells.

Arisi MF, Starker RA, Addya S, Huang Y, Fernandez SV.

Int J Oncol. 2014 Jun;44(6):1831-42. doi: 10.3892/ijo.2014.2354.


The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene.

Chua YL, Ito Y, Pole JC, Newman S, Chin SF, Stein RC, Ellis IO, Caldas C, O'Hare MJ, Murrell A, Edwards PA.

Oncogene. 2009 Nov 19;28(46):4041-52. doi: 10.1038/onc.2009.259.


Estrogen and xenoestrogens in breast cancer.

Fernandez SV, Russo J.

Toxicol Pathol. 2010 Jan;38(1):110-22. doi: 10.1177/0192623309354108. Review.


Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.

Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, Knüchel R, Dahl E.

Breast Cancer Res. 2008;10(5):R82. doi: 10.1186/bcr2151.


Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications.

Müller I, Wischnewski F, Pantel K, Schwarzenbach H.

BMC Cancer. 2010 Jun 17;10:297. doi: 10.1186/1471-2407-10-297.


Epithelial to mesenchymal transition in human breast epithelial cells transformed by 17beta-estradiol.

Huang Y, Fernandez SV, Goodwin S, Russo PA, Russo IH, Sutter TR, Russo J.

Cancer Res. 2007 Dec 1;67(23):11147-57.


Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.

Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC Jr, Yu Y.

Cancer Res. 2003 Jul 15;63(14):4174-80.


Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer.

Douglas DB, Akiyama Y, Carraway H, Belinsky SA, Esteller M, Gabrielson E, Weitzman S, Williams T, Herman JG, Baylin SB.

Cancer Res. 2004 Mar 1;64(5):1611-20.


Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.

Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6189-93.


Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.

Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA, Palazzo J, McCue PA, Baffa R, Huebner K.

Oncogene. 2005 Feb 24;24(9):1625-33.


Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.

Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knüchel R, Dahl E.

Mol Cancer. 2008 Nov 6;7:83. doi: 10.1186/1476-4598-7-83.


Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.

Borges S, Döppler H, Perez EA, Andorfer CA, Sun Z, Anastasiadis PZ, Thompson E, Geiger XJ, Storz P.

Breast Cancer Res. 2013 Aug 23;15(2):R66. doi: 10.1186/bcr3460.

Supplemental Content

Support Center